|
Suicide rating’ could be given to every new drug licensed in UK
Every new drug licensed in Britain will be given a "suicide rating" under proposals for a big shake-up in the rules governing pharmaceutical development. European regulators are also to require pharmaceutical companies to include a comprehensive suicide assessment into trials of new medicines. The reform, based on a system adopted recently in the United States, has been fuelled by a growing body of evidence that drugs that affect the brain can heavily influence behaviour through seemingly innocuous changes in body chemistry. Medicines to treat acne, swelling, heartburn, pain, obesity, high blood pressure and cholesterol, bacterial infections, smoking and insomnia have all been associated recently with psychiatric problems. There have been warnings about the potential side-effects of Acomplia, an antiobesity drug, Roaccutane, an acne treatment, and Champix, an antismoking medication, which together have been prescribed to more than 60,000 patients in Britain.
Camera with built-in GPS to be unveiled at PMA?
Well, that's what the folks over at the Geotate booth were talking about during the PMA Sneak Peek event held today at the Las Vegas Convention Center. According to them, the camera will be developed by a Taiwanese vendor and introduced under a branded camera name during PMA.
Geotate believes that its GPS geotagging solution can overcome common issues faced by other similar devices in the market today such as sluggish GPS response and power drain. This is achieved by separating the GPS data capture and processing. Once the shutter is pressed, the GPS data is stored in the memory and will only be processed when it is transferred to the PC and connected to Geotate's server.
.
Novacta Receives 3.5 Million Pounds Strategic Translation Award From ...
Novacta Biosystems, a UK-based anti-infective therapeutics company, announces that the Wellcome Trust, the UK's largest medical research charity, has awarded it £3.5 million as part of the Trust's Strategic Translational Award programme. Novacta will use the award to progress development of a drug which, it is hoped, will help combat hospital-based Clostridium difficile (C.difficile) infections.
C. Difficile infections (CDIs) are a growing and serious problem and have, for example, been associated with twice as many deaths in UK hospitals last year as MRSA. Cases of C.difficile infections, which occur in the lower digestive tract, rose by 22 per cent in the past year and affected more than 15,500 people over 65 in the first quarter of 2007. New anti-infective drugs are needed to target C.difficile without depleting other beneficial bacteria in the gut.
Vines: Priorities change for Strader
State Rep. Parkey Strader said battling liver cancer has given him a change in priorities, and "you will not see Parkey on the ballot again." The Republican who represents the 14th District in northwest Knox County disclosed last week that he will not seek re-election after two terms. He previously served as property assessor, first getting elected in 1972 and serving until 2000. He then became chief deputy in the assessor's office. Strader was diagnosed with cancer on July 5, 2006. A doctor at the M.D. Anderson Cancer Center in Houston told him he could expect to live 13 months. It's now going on almost 1 1/2 years, he said. He's had multiple surgeries and other treatment. "Prayers do work," he said. Strader announced he is resigning as chief deputy to Knox County Property Assessor John Whitehead effective Dec.
Alma(TM) Lasers to Debut Five New Products at the 66th Annual Meeting ...
BUFFALO GROVE, Ill., Feb. 1 /PRNewswire/ -- Alma Lasers Ltd. ("Alma Lasers"), a global developer and marketer of laser, intense pulsed light, and radiofrequency-based aesthetic devices, announced today that it will unveil five new products at the 66th Annual Meeting of the American Academy of Dermatology (AAD) in San Antonio, Texas, from February 2nd to 4th. Company representatives will be available during this time to discuss Alma Lasers' full line of products in booth #4465 at the Henry B. Gonzalez Convention Center. These new products include the Harmony(XL) Multi-Application System, Pixel CO2 OmniFit handpiece, Pixel Er OmniFit handpiece, Pixel CO2 System and Accent(XL) UniLarge handpiece. The Harmony(XL) has more power, five new contact-cooled handpieces, a high-powered Pixel(TM) 2940 for fractional ablative skin resurfacing, Pain-Free Hair Removal, and a LED handpiece for post-treatment erythema.
|
